Presentation

Gentian Diagnostics AS is a medical diagnostics company listed on the Oslo Stock Exchange, Merkur Market. The company performs production, R&D, marketing and distribution of immunoassays at our headquarters in Norway and we are supported globally by our distribution subsidiaries in Sweden, the USA and a representative office in China.

Gentian serves the immunochemistry segment of the in vitro diagnostics (IVD) market with products which add value to healthcare suppliers by improving laboratory workflow and clinical outcome. The value propositions of new products will be scientifically proven and promoted by investments into clinical studies, state-of-the art marketing and selective commercial representation in focus countries.

Through in-depth research into Particle-Enhanced Turbidimetric Immunoassays (PETIA), and the development of proprietary antibody and nano-particle technology, Gentian’s immunoassays enable users to move assays from low volume immunology platforms to fully automated, high throughput instruments with shorter turnaround times, better workflow and improved cost efficiency. Gentian’s current portfolio includes Cystatin C (CE marked and FDA-510(k) cleared), the calprotectin immunoassay GCAL® (CE marked, US: RUO) and Canine CRP. Gentian is also the sole reagent provider and manufacturer for the faecal calprotectin immunoassay fCAL® turbo (CE marked and FDA-510(k) cleared) in addition to the newly launched, pancreatic elastase immunoassay fPELA® turbo (CE marked, FDA Exempt). These immunoassays are sold through Gentian’s partner BÜHLMANN.

In addition, the subsidiary PreTect AS develops and manufactures molecular diagnostic tests to detect oncogenic activity in cervical samples. The products PreTect SEE and PreTect HPV-Proofer contribute to earlier detection of cervical cancer.